Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer
To evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin for Chinese patients with triple-negative and HER2-positive breast cancer in the neoadjuvant setting.
Breast Cancer|Triple Negative Breast Cancer|HER2-positive Breast Cancer
DRUG: Nab-paclitaxel|DRUG: Carboplatin|DRUG: Herceptin
Pathological complete response (ypT0/is ypN0) rate, Absence of invasive cancer in the breast and axillary nodes, irrespective of ductal carcinoma in situ., 16 weeks (at the time of definitive surgery)
Invasive disease-free survival (IDFS), IDFS is defined as the time period between registration and first event (ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, death attributable to any cause, contralateral invasive breast cancer, second primary nonbreast invasive cancer), 5 years|Distant disease-free survival (DDFS), DDFS is defined as the time period between registration and first event (distant recurrence, death attributable to any cause, second primary nonbreast invasive cancer), 5 years|Objective response rate (ORR), ORR includes all patients whose cancer has a partial or complete response according to RECIST 1.1, 16 weeks (at the time of definitive surgery)|Breast conservation rate, To determine the breast conservation rate after neoadjuvant treatment., 16 weeks (at the time of definitive surgery)|Tolerability and safety: number of patients whose treatment had to be reduced, delayed or permanently stopped, Descriptive statistics will be given on the number of patients whose treatment had to be reduced, delayed or permanently stopped., during treatment (16 weeks)
To evaluate the efficacy and safety of nab-paclitaxel combined with carboplatin for Chinese patients with triple-negative and HER2-positive breast cancer in the neoadjuvant setting.